1
|
Sviripa VM, Fiandalo MV, Begley KL, Wyrebek P, Kril LM, Balia AG, Parkin SR, Subramanian V, Chen X, Williams AH, Zhan CG, Liu C, Mohler JL, Watt DS. Pictet-Spengler condensations using 4-(2-aminoethyl)coumarins. NEW J CHEM 2020; 44:13415-13429. [PMID: 33795928 DOI: 10.1039/d0nj02664f] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Androgen-deprivation therapy (ADT) is only a palliative measure, and prostate cancer invariably recurs in a lethal, castration-resistant form (CRPC). Prostate cancer resists ADT by metabolizing weak, adrenal androgens to growth-promoting 5α-dihydrotestosterone (DHT), the preferred ligand for the androgen receptor (AR). Developing small-molecule inhibitors for the final steps in androgen metabolic pathways that utilize 17-oxidoreductases required probes that possess fluorescent groups at C-3 and intact, naturally occurring functionality at C-17. Application of the Pictet-Spengler condensation to substituted 4-(2-aminoethyl)coumarins and 5α-androstane-3-ones furnished spirocyclic, fluorescent androgens at the desired C-3 position. Condensations required the presence of activating C-7 amino or N,N-dialkylamino groups in the 4-(2-aminoethyl)coumarin component of these condensation reactions. Successful Pictet-Spengler condensation, for example, of DHT with 9-(2-aminoethyl)-2,3,6,7-tetrahydro-1H,5H,11H-pyrano[2,3-f]pyrido[3,2,1-ij]quinolin-11-one led to a spirocyclic androgen, (3R,5S,10S,13S,17S)-17-hydroxy-10,13-dimethyl-1,2,2',3',4,5,6,7,8,8',9,9',10,11,12,12',13,13',14,15,16,17-docosahydro-7'H,11'H-spiro-[cyclopenta[a]phenanthrene-3,4'-pyrido[3,2,1-ij]pyrido[4',3':4,5]pyrano[2,3-f]quinolin]-5'(1'H)-one. Computational modeling supported the surrogacy of the C-3 fluorescent DHT analog as a tool to study 17-oxidoreductases for intracrine, androgen metabolism.
Collapse
Affiliation(s)
- Vitaliy M Sviripa
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY 40536-0596 USA.,Center for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky, Lexington, KY 40536-0596 USA.,Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, KY 40536-0093 USA
| | - Michael V Fiandalo
- Department of Experimental Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263 USA
| | - Kristin L Begley
- Center for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky, Lexington, KY 40536-0596 USA.,Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY 40536-0509 USA
| | - Przemyslaw Wyrebek
- Center for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky, Lexington, KY 40536-0596 USA.,Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY 40536-0509 USA
| | - Liliia M Kril
- Center for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky, Lexington, KY 40536-0596 USA.,Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY 40536-0509 USA
| | - Andrii G Balia
- Center for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky, Lexington, KY 40536-0596 USA.,Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY 40536-0509 USA
| | - Sean R Parkin
- Department of Chemistry, College of Arts and Sciences, University of Kentucky, Lexington, KY 40506 USA
| | | | - Xi Chen
- College of Chemistry and Material Science, South Central University for Nationalities, Wuhan 430074, People's Republic of China
| | - Alexander H Williams
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY 40536-0596 USA
| | - Chang-Guo Zhan
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY 40536-0596 USA.,Center for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky, Lexington, KY 40536-0596 USA
| | - Chunming Liu
- Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, KY 40536-0093 USA.,Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY 40536-0509 USA
| | - James L Mohler
- Department of Experimental Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263 USA.,Department of Urology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263 USA
| | - David S Watt
- Center for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky, Lexington, KY 40536-0596 USA.,Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, KY 40536-0093 USA.,Department of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY 40536-0509 USA
| |
Collapse
|
2
|
Hisamatsu Y, Fukiage T, Honma K, Balia AG, Umezawa N, Kato N, Higuchi T. Effect of the o-Acetamido Group on pH-Dependent Light Emission of a 3-Hydroxyphenyl-Substituted Dioxetane Luminophore. Org Lett 2019; 21:1258-1262. [PMID: 30767544 DOI: 10.1021/acs.orglett.8b03913] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Abstract
A pioneering chemiluminescent molecule reported by Schaap and co-workers, 3-(2'-spiroadamantane)-4-methoxy-4-(3″-hydroxy)phenyl-1,2-dioxetane (AMPD), does not require enzymatic activation but is unsuitable for use under physiological conditions. To overcome this limitation, we have developed a new AMPD derivative that contains an acetamido group at the ortho position of the hydroxy group as an intramolecular hydrogen-bonding site in order to lower the p Ka value. This compound exhibits a superior chemiluminescence response to AMPD in the physiologically relevant pH range.
Collapse
Affiliation(s)
- Yosuke Hisamatsu
- Graduate School of Pharmaceutical Sciences , Nagoya City University , 3-1 Tanabe-dori , Mizuho-ku , Nagoya 467-8603 , Japan
| | - Takehiro Fukiage
- Graduate School of Pharmaceutical Sciences , Nagoya City University , 3-1 Tanabe-dori , Mizuho-ku , Nagoya 467-8603 , Japan
| | - Kojiro Honma
- Graduate School of Pharmaceutical Sciences , Nagoya City University , 3-1 Tanabe-dori , Mizuho-ku , Nagoya 467-8603 , Japan
| | - Andrii G Balia
- Graduate School of Pharmaceutical Sciences , Nagoya City University , 3-1 Tanabe-dori , Mizuho-ku , Nagoya 467-8603 , Japan
| | - Naoki Umezawa
- Graduate School of Pharmaceutical Sciences , Nagoya City University , 3-1 Tanabe-dori , Mizuho-ku , Nagoya 467-8603 , Japan
| | - Nobuki Kato
- Graduate School of Pharmaceutical Sciences , Nagoya City University , 3-1 Tanabe-dori , Mizuho-ku , Nagoya 467-8603 , Japan
| | - Tsunehiko Higuchi
- Graduate School of Pharmaceutical Sciences , Nagoya City University , 3-1 Tanabe-dori , Mizuho-ku , Nagoya 467-8603 , Japan
| |
Collapse
|
3
|
Sviripa VM, Zhang W, Balia AG, Tsodikov OV, Nickell JR, Gizard F, Yu T, Lee EY, Dwoskin LP, Liu C, Watt DS. 2',6'-Dihalostyrylanilines, pyridines, and pyrimidines for the inhibition of the catalytic subunit of methionine S-adenosyltransferase-2. J Med Chem 2014; 57:6083-91. [PMID: 24950374 PMCID: PMC4111374 DOI: 10.1021/jm5004864] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
![]()
Inhibition
of the catalytic subunit of the heterodimeric methionine
S-adenosyl transferase-2 (MAT2A) with fluorinated N,N-dialkylaminostilbenes (FIDAS agents) offers a
potential avenue for the treatment of liver and colorectal cancers
where upregulation of this enzyme occurs. A study of structure–activity
relationships led to the identification of the most active compounds
as those with (1) either a 2,6-difluorostyryl or 2-chloro-6-fluorostyryl
subunit, (2) either an N-methylamino or N,N-dimethylamino group attached in a para orientation relative to the 2,6-dihalostyryl subunit, and (3) either
an N-methylaniline or a 2-(N,N-dimethylamino)pyridine ring. These modifications led to
FIDAS agents that were active in the low nanomolar range, that formed
water-soluble hydrochloride salts, and that possessed the desired
property of not inhibiting the human hERG potassium ion channel at
concentrations at which the FIDAS agents inhibit MAT2A. The active
FIDAS agents may inhibit cancer cells through alterations of methylation
reactions essential for cancer cell survival and growth.
Collapse
Affiliation(s)
- Vitaliy M Sviripa
- Department of Molecular and Cellular Biochemistry, ‡Department of Pharmaceutical Sciences, College of Pharmacy, §Center for Pharmaceutical Research and Innovation, and ∥Markey Cancer Center, University of Kentucky , Lexington, Kentucky 40506-0509, United States
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|